Inhaled drug could offer new hope for lung scarring disease
NCT ID NCT07679893
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 2 trial tests whether an inhaled form of nintedanib (MNKD-201) is safe and effective for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. About 210 adults with IPF will receive either a low or high dose of the inhaled drug or a placebo for 12 weeks, followed by a period where everyone gets the active drug. The study focuses on safety, especially breathing problems right after inhalation, and changes in lung function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nintedanib dry powder inhalation
What this could lead to
If successful, this could offer a more targeted, inhaled treatment for IPF, potentially reducing side effects compared to the oral version.
What could go wrong
This is an early phase 2 trial with a small number of participants. The inhaled drug may cause bronchospasm or other side effects, and it may not prove effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mannkind Corporation
Danbury, Connecticut, 06810, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••